The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy

Abstract

Background: Atezolizumab, an immune checkpoint inhibitor, in combination with chemotherapy (chemoimmunotherapy) has become a first-line treatment option for metastatic non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) are self-reported measures that have shown promise in their predictive value for survival. However, there have been no studies that have assessed the prognostic performance of PROs in an advanced NSCLC cohort initiating first-line atezolizumab based chemoimmunotherapy.Methods: This study used individual-participant data (IPD) from the IMpower130, IMpower131 and IMpower150 clinical trials. Cox proportional hazards regression was utilized to determine the association between pre-treatment PROs with overall survival (OS) and progression free survival (PFS). The prediction performance of PROs was assessed using the C-statistic. For the PRO measure identified as the most predictive of survival, an exploratory analysis comparing the predictive performance against Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was conducted.

The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project

“…Lastly, the present study highlights the relevance of understanding and appreciating information. Results suggest that general cognitive function abilities predict decision‐making capacity, 27 as supported by the biomedical literature 42,45 . Therefore, patients who show difficulties in understanding information could benefit from enhanced support, such as receiving information through multiple methods (e.g., hearing and seeing).…”

“…Results suggest that general cognitive function abilities predict decision‐making capacity, 27 as supported by the biomedical literature. 42 , 45 Therefore, patients who show difficulties in understanding information could benefit from enhanced support, such as receiving information through multiple methods (e.g., hearing and seeing). Moreover, patients could be provided with summaries of information and enough time to paraphrase what was explained, reviewing information again with the physician.…”

Network analysis of quality of life in older breast cancer patients: A cross-sectional research from China

“…The study covered patients at all stages of treatment, including those in advanced stages. Such patients have a poorer quality of life and more severe symptoms of fatigue as a result of multi-line treatment (29). A previous multicenter, large prospective cohort study showed that disease progression in cancer patients was signi cantly associated with a decline in quality of life, with the greatest impact on appetite, physical function, and fatigue (30).…”

Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer

“…However, this index measures functional status but does not assess the cause, and as a result, very different patients may be categorized with the same PS. The ECOG PS scale is influenced by different aspects, such as the burden of the disease itself, the presence of comorbidities and the global frailty of elderly people [16].…”